Home LiteratureArticle Details
PMID: 23796475 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.

Journal of hepatology ·Vol. 59 ·No. 5 ·2013-11-00 ·Pages 1007-13

Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF

Abstract

Myeloid derived suppressor cells (MDSC) are immature myeloid cells with immunosuppressive activity. They accumulate in tumor-bearing mice and humans with different types of cancer, including hepatocellular carcinoma (HCC). The aim of this study was to examine the biology of MDSC in murine HCC models and to identify a model, which mimics the human disease. The comparative analysis of MDSC was performed in mice, bearing transplantable, diethylnitrosoamine (DEN)-induced and MYC-expressing HCC at different ages. An accumulation of MDSC was found in mice with HCC irrespective of the model tested. Transplantable tumors rapidly induced systemic recruitment of MDSC, in contrast to slow-growing DEN-induced or MYC-expressing HCC, where MDSC numbers only increased intra-hepatically in mice with advanced tumors. MDSC derived from mice with subcutaneous tumors were more suppressive than those from mice with DEN-induced HCC. Enhanced expression of genes associated with MDSC generation (GM-CSF, VEGF, IL6, IL1β) and migration (MCP-1, KC, S100A8, S100A9) was observed in mice with subcutaneous tumors. In contrast, only KC levels increased in mice with DEN-induced HCC. Both KC and GM-CSF overexpression or anti-KC and anti-GM-CSF treatment controlled MDSC frequency in mice with HCC. Finally, the frequency of MDSC decreased upon successful anti-tumor treatment with sorafenib. Our data indicate that MDSC accumulation is a late event during hepatocarcinogenesis and differs significantly depending on the tumor model studied.

Keywords
BLR Cancer vaccine DEN G-CSF GM-CSF HCC IL Immunotherapy KC L-NMMA LAP MCP MDSC N(G)-methyl-L-arginine N(ω)-hydroxil-nor-L-arginine N-NOHA NK OVA Tumor immunology VEGF WT body weight/liver weight ratio diethylnitrosoamine granulocyte colony stimulating factor granulocyte-macrophage colony stimulating factor hepatocellular carcinoma iNOS inducible nitric oxide synthase interleukin keratinocyte-derived chemokine liver activator protein macrophage chemotactic protein myeloid derived suppressor cell natural killer ovalbumin vascular endothelial growth factor wild type
MeSH Terms
Animals Antineoplastic Agents/pharmacology Carcinoma, Hepatocellular/chemically induced,metabolism,pathology Cell Movement/drug effects Cell Proliferation/drug effects Diethylnitrosamine/adverse effects Disease Models, Animal Granulocyte-Macrophage Colony-Stimulating Factor/metabolism Heterografts Humans Liver Neoplasms/chemically induced,metabolism,pathology Mice Mice, Inbred BALB C Mice, Inbred C57BL Myeloid Cells/drug effects,pathology Niacinamide/analogs & derivatives,pharmacology Phenylurea Compounds/pharmacology Proto-Oncogene Proteins c-myc/metabolism Sorafenib
Chemicals
Antineoplastic Agents Phenylurea Compounds Proto-Oncogene Proteins c-myc Niacinamide Diethylnitrosamine Granulocyte-Macrophage Colony-Stimulating Factor Sorafenib
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Kapanadze Tamar
Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, USA; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Gamrekelashvili Jaba
Ma Chi
Chan Carmen
Zhao Fei
Hewitt Stephen
Zender Lars
Kapoor Veena
Felsher Dean W
Manns Michael P
Korangy Firouzeh
Greten Tim F
References (41)
41 references, click to expand
  1. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
    Semin Cancer Biol. 2012 Aug;22(4):275-81 PMID: 22313874
  2. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  3. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.
    Cancer Cell. 2012 Jun 12;21(6):822-35 PMID: 22698406
  4. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
    Lab Invest. 2011 Apr;91(4):598-608 PMID: 21321535
  5. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
    J Immunol. 2010 Jul 1;185(1):203-10 PMID: 20525890
  6. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
    Eur J Immunol. 2010 Jan;40(1):22-35 PMID: 19941314
  7. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  8. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.
    J Immunol. 2001 May 1;166(9):5398-406 PMID: 11313376
  9. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.
    Nature. 2004 Oct 28;431(7012):1112-7 PMID: 15475948
  10. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse.
    Cancer Res. 1983 Sep;43(9):4253-9 PMID: 6871863
  11. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
    Blood. 1998 Dec 1;92(11):4150-66 PMID: 9834220
  12. Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice.
    PLoS One. 2011 Mar 04;6(3):e17631 PMID: 21394214
  13. Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.
    J Leukoc Biol. 2012 Dec;92(6):1199-206 PMID: 23077247
  14. Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.
    Semin Cancer Biol. 2012 Aug;22(4):282-8 PMID: 22313876
  15. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
    J Immunol. 2009 Jan 1;182(1):240-9 PMID: 19109155
  16. Experimental mouse models for hepatocellular carcinoma research.
    Int J Exp Pathol. 2009 Aug;90(4):367-86 PMID: 19659896
  17. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.
    Blood. 2008 Jun 15;111(12):5457-66 PMID: 18375791
  18. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
    Gut. 2012 Dec;61(12):1733-43 PMID: 22267597
  19. Myeloid derived suppressor cells in human diseases.
    Int Immunopharmacol. 2011 Jul;11(7):802-7 PMID: 21237299
  20. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.
    J Immunol. 2008 Oct 1;181(7):4666-75 PMID: 18802069
  21. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.
    J Immunol. 2006 Jan 1;176(1):284-90 PMID: 16365420
  22. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
    Cancer Immunol Immunother. 2010 Jan;59(1):47-62 PMID: 19449184
  23. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  24. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.
    Cancer Immunol Immunother. 2011 Oct;60(10):1419-30 PMID: 21644036
  25. Serum cytokine levels in patients with hepatocellular carcinoma.
    Eur Cytokine Netw. 2010 Jun;21(2):99-104 PMID: 20478763
  26. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.
    PLoS One. 2011;6(11):e27690 PMID: 22110722
  27. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression.
    Cancer Res. 2009 Jul 1;69(13):5514-21 PMID: 19549903
  28. Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
    J Immunol. 2008 Oct 15;181(8):5791-802 PMID: 18832739
  29. Hepatocellular carcinoma pathogenesis: from genes to environment.
    Nat Rev Cancer. 2006 Sep;6(9):674-87 PMID: 16929323
  30. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.
    Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 PMID: 8855286
  31. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.
    Cancer Res. 2011 Mar 15;71(6):2286-97 PMID: 21262914
  32. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors.
    Cold Spring Harb Symp Quant Biol. 2005;70:251-61 PMID: 16869761
  33. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    J Exp Med. 2010 Oct 25;207(11):2439-53 PMID: 20876310
  34. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.
    Hepatology. 2009 Sep;50(3):799-807 PMID: 19551844
  35. Subsets, expansion and activation of myeloid-derived suppressor cells.
    Med Microbiol Immunol. 2010 Aug;199(3):273-81 PMID: 20376485
  36. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
    Cancer Res. 2004 Sep 1;64(17):6337-43 PMID: 15342423
  37. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.
    J Immunol. 2004 Jan 15;172(2):989-99 PMID: 14707072
  38. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.
    J Leukoc Biol. 2010 Apr;87(4):713-25 PMID: 20042467
  39. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
    J Immunol. 1999 May 15;162(10):5728-37 PMID: 10229805
  40. The terminology issue for myeloid-derived suppressor cells.
    Cancer Res. 2007 Jan 1;67(1):425; author reply 426 PMID: 17210725
  41. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Gastroenterology. 2008 Jul;135(1):234-43 PMID: 18485901
Article Info
Journal
Journal of hepatology
Abbr.
J Hepatol
ISSN
1600-0641
Published
2013-11-00
Epub
2013-00-22
Pages
1007-13
Language
English
Region
Netherlands
NLM ID
8503886
PMCID
PMC3805787
Subset
IM
Grants
Intramural NIH HHS · ZIA BC011346-01 · United States
Intramural NIH HHS · ZIA BC011346-02 · United States
Intramural NIH HHS · ZIA BC011346-03 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com